20 BODY CARE


the skin’s defences.9,10 S. epidermidis can benefit the skin in several


ways, such as reducing inflammation after injury, improving the development of cutaneous T-cells,12


producing lipoteichoic acid that


modulates inflammation, and stimulating keratinocytes to produce antimicrobial peptides.8


This enhances the skin’s defence


against infection by inhibiting pathogenic microorganisms such as Streptococcus and Staphylococcus aureus.9,10


Studies


indicate that S. epidermidis inhibits colonization through the induction of glutamyl endopeptidase and β-defensin expression, as well as the formation of biofilm by S. aureus.9 In contrast, Staphylococcus aureus is an opportunistic pathogen widely recognized for causing skin and soft tissue infections, such as boils, carbuncles, and abscesses.11,2


responsible for approximately 75% of primary pyodermas.2 S. aureus infections often begin as minor


boils or abscesses and may progress to severe infections involving muscle or bone, and can spread to the lungs or heart valves.2


Pre-existing


conditions, such as tissue injury (ulcers, wounds) or tissue inflammation (exudative dermatitis), as well as underlying disorders (such as diabetes mellitus or poorly controlled insulin-dependent cancer), are some of the risk factors for S. aureus infection.11


Microbiome-friendly deodorant ingredient Aligned with market trends, Chemyunion has developed Hebeatol® Plus DEO, hereafter described as the deodorant ingredient, is a natural ingredient derived from renewable sources and based on an easily biodegradable molecule. It effectively controls odour-causing microorganisms, providing long-lasting deodorant protection while maintaining a microbiome- friendly profile. A comparative, randomized, placebo-


controlled, single-blind clinical study was conducted to assess the modulation of microbial populations (Staphylococcus aureus and Staphylococcus epidermidis) present in the axillary region. The objective was to evaluate the efficacy


S.aureus


4.00 3.50 3.00 2.50 2.00 1.50 1.00 0.50 0.00


** 0.64 # *** 0.31 1.1 1.19


■ On the second visit, compliance with the conditioning period and study guidelines was verified. A microbiological sample was collected from both axillae using a sterile swab (T0). The first application of the products (investigational and placebo) was then carried out, according to randomization, on the right and left axillae. After 1 hour, a second microbiological collection from both axillae was performed (T1h). ■ On the third visit, 24 hours after the first application of the investigational product and placebo, another microbiological collection from both axillae was carried out


S. aureus is


of a deodorant formulation containing the deodorant ingredient at 0.35% w/w compared to a placebo in maintaining and/or controlling skin microorganisms. This was achieved through non-invasive swab sampling and microbiological analysis of S. aureus and S. epidermidis under normal use conditions. Before starting the clinical test, the deodorant


formulation with 0.35% p/p deodorant ingredient was subjected to the HRIPT test (Human Repeated Insult Patch Test), a standard clinical test used primarily in the cosmetic, personal care, and pharmaceutical industries to assess a product’s potential for skin sensitization and irritation: No primary dermal irritation potential was


observed; no cumulative dermal irritation potential was observed; no dermal sensitization potential was observed. According to the recommendation of the


Cosmetic Product Safety Evaluation Guide (ANVISA, 2012 – 2nd Edition), the product can be declared ‘dermatologically tested’.15 The sample collection was carried out as


follows: ■ During the first visit (T-7), an initial clinical evaluation was performed by a dermatologist to confirm the inclusion criteria. Participants received the auxiliary product (neutral soap), which was to be used during the conditioning period and throughout the entire study.


T0 ■ T21D ■ # ***


(T24h). Participants were instructed to continue using the investigational product and placebo on the axillae assigned by randomization for 21 days. After this period, they returned to the institute for the final microbiological evaluation of the axillae (T21d).


Clinical study The study was conducted over 21 days, with evaluations performed at T0, T1h, T24h, and T21d. The application area was the underarm region, with once-daily use. The study included 20 female volunteers, aged 24–67 years (mean age 49), all regular users of roll-on deodorants. Eighteen completed the study protocol.


Participants were instructed to apply the investigational product, the placebo, and a neutral glycerin soap (as an auxiliary product) once daily after bathing. The data were analysed according to age group (Table 1). The total population (n = 18) ranged from 31


to 67 years and was classified as “30+.” A second subset with significant differences in results was identified as “55+” (n = 8). Additional statistical analyses were conducted on these subgroups. Samples were tested for normality using the


Shapiro-Wilk test. Statistical differences between groups were assessed using either the Student’s t-test or the Wilcoxon test, depending on the distribution of the data. Results with p-values < 0.05 were considered statistically significant. Statistical analysis of the raw data revealed


more pronounced and significant variations between the 30+ and 55+ groups, and between T0 and T21d, when comparing the placebo versus the deodorant ingredient formulation at 0.35% w/w. After 21 days of treatment, statistically


significant differences were observed between the placebo and the formulation containing the deodorant ingredient 0.35% for the S. aureus population (Figure 1). Differences or trends were observed in both


age groups, in contrast to the S. epidermidis population, where no significant reduction was observed (Figure 2).


Placebo 30+


With Hebeatol® Plus DEO


Placebo 55+


Figure 1: Mean and standard error for S. aureus modulation comparing placebo versus the deodorant ingredient 0.35%, in the 30+ and 55+ age groups


PERSONAL CARE MAGAZINE February 2026


With Hebeatol® Plus DEO


Conclusion These findings indicate that the deodorant ingredient contributes to the control and reduction of the pathogenic microorganism Staphylococcus aureus while supporting the maintenance of the beneficial microorganism Staphylococcus epidermidis.16


www.personalcaremagazine.com


Log of Microorganisms count


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72